Samuel Kintz, President and CEO: Enliven Therapeutics ELVN Sell · Filed 25/10/21

Trade details

Type: Insider sale
Amount: $266,625
Shares · price: 12,500 sh · $21.33 a share
Held after: 902,892 sh
Stock: Enliven Therapeutics ELVN
Person: Samuel KintzPresident and CEO
Trade date: 25/10/17
Filed: 25/10/21
Days to filing: 4 days

Sold 1.4% of holdings

Share of holding sold: 1.4%

Enliven Therapeutics trades, last 26 weeks

What else happened in Enliven Therapeutics around then

Filed or reported within 30 days of the trade day · 25/09/17~25/11/16

Samuel Kintz's recent trades

Samuel KintzPresident and CEO
Planned sale10b5-1 planEnliven Therapeutics
Planned sale10b5-1 plan
Enliven Therapeutics
ELVN
$2M
75,000 sh
$2M
Filed 02/17
Traded 02/17
Samuel KintzPresident and CEO
Planned sale10b5-1 planEnliven Therapeutics
Planned sale10b5-1 plan
Enliven Therapeutics
ELVN
$1.7M
75,000 sh
$1.7M
Filed 01/09
Traded 01/09
Samuel KintzPresident and CEO
Planned sale10b5-1 planEnliven Therapeutics
Planned sale10b5-1 plan
Enliven Therapeutics
ELVN
$1.3M
82,500 sh
$1.3M
Filed 01/08
Traded 01/08
Samuel KintzPresident and CEO
Planned sale10b5-1 planEnliven Therapeutics
Planned sale10b5-1 plan
Enliven Therapeutics
ELVN
$84.6K
5,000 sh
$84.6K
Filed 25/12/17
Traded 25/12/17
Samuel KintzPresident and CEO
Sell10b5-1 planEnliven Therapeutics
Sell10b5-1 plan
Enliven Therapeutics
ELVN
$272.8K
12,500 sh
$272.8K
Filed 25/11/19
Traded 25/11/17